Barron’s Top Weekend Stock Picks: BYD, Coinbase, DoorDash And Why Musk Would Be A Hero By Banning This Twitter Account
Benzinga reviews this weekend's top stories covered by Barron's, here are the articles investors need to read.
Bulls And Bears Of The Week: Apple, Amazon, Microsoft, And Why Dogecoin Is Showing Resilience Amid FTX Aftershock
Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories.
Who Are The Winners And Losers Of G7 Price Cap On Russian Oil?
Ahead of the OPEC + meeting this Sunday to discuss its oil production policy, the European Union decided to ban all maritime transports of imported Russian oil on Monday.
2 High-Yielding Grocery REITs Offer Best ‘Bang For Your Buck’ As A Global Recession Looms
Although the all-items index increased 7.7% for the twelve months ending October, this was the smallest 12-month increase since the period ending January 2022.
Meanwhile, food inflation increased by 0.6% in October to 10.9% unadjusted year-over-year.
These 2 Global Bankers Tout Attractive Yields That Have Been Growing For Years
The Invesco KBW Bank ETF (NASDAQ: KBWB) is down roughly 19% year-to-date, compared to the S&P 500 which is down at least 16% year-to-date.
A Philanthropic Activist Investor Maintains Stakes In 2 Canadian Railroad Stocks Paying Dividends
British billionaire Chris Hohn is an activist investor who founded The Children's Investment (TCI) Fund Management in 2003. The fund manages The Children's Investment Master Fund.
Is The Hedge Fund Love Affair With Tech Stocks Over? Goldman Sachs Data Provides A Clue
When the COVID-19 pandemic struck in 2020, labor, education and retail went virtual with tech companies of all stripes seeing a boom.
Big tech performed especially well and hedge funds played a significant role in the purchase of those equities.
Analyst Forecasts $101-117/Share Offer Price For Horizon Therapeutics’ Buyout
Horizon Therapeutics Plc (NASDAQ:HZNP) confirmed it’s engaged in preliminary talks with Amgen Inc (NASDAQ:AMGN), Janssen Global Service, and Sanofi SA SNY on potential takeover offers for…
Despite Safety Concerns, Analysts Are Bullish On Biogen’s Second Alzheimer’s Candidate
Eisai Limited (OTC: ESALY) and partner Biogen Inc (NASDAQ: BIIB) presented detailed data from the positive Phase 3 CLARITY-AD study of lecanemab in early Alzheimer's disease (AD).
Regeneron’s Evkeeza Under FDA Priority Review For Younger Kids With Inherited Form Of High Cholesterol
The FDA has accepted Regeneron Pharmaceuticals Inc’s (NASDAQ:REGN) supplemental marketing application seeking approval for Evkeeza (evinacumab-dgnb) as an adjunct to other…